GlobeNewswire by notified

Photocat strengthens its position in Switzerland within Sustainable Solutions through partnership with Hydag AG


October 31st 2023

Photocat strengthens its position in Switzerland within Sustainable Solutions through partnership with Hydag AG

Roskilde, Denmark. October 31st, 2023 – Photocat, a global leader and innovator of sustainable solutions, is proud to announce a strategic commercial partnership with Hydag AG, a Swiss leader in techno-chemical technologies. This partnership signals a significant step forward in Photocat's mission to revolutionize the world with sustainable and eco-friendly solutions.

Key Partnership Highlights:

  • Expanding Photocat's marketplace for CMA Suite of Products: Road salt has been used for many years with acceptance of the significant negative side effects like corrosion, negative effect of water and plants. Photocat solution has changed this completely to offer both significant economic advantages as well as significant advantages in reduction of PM 1, 2.5 and 10 in the air bringing a much more desirable health benefit to citizens. As part of this collaboration, Photocat's cutting-edge CMA suite of de-icing products will be at the forefront of enhancing environmental performance across various sectors. These products are designed to cater to a wide range of applications and stand out due to its documented benefits over traditional road salt.

  • Harnessing Photocatalytic Technologies: Photocat's suite of photocatalytic technologies will play a pivotal role in this partnership. These innovative technologies utilize the power of light and photocatalysis to break down pollutants (NOx) as well as Volatile Organic Components (VOCs) and hence ensuring cleaner and more sustainable environments in metropolitan and densely populated areas.

  • Initial Order of 18 Pallets for Commercialization: Hydag AG has placed an initial order for 18 pallets of Photocat's CMA suite of products, signifying a strong commitment to introducing these innovative solutions to the market. This order represents the beginning of a transformative journey towards providing effective and eco-friendly de-icing solutions to the Swiss market.

  • Financial impact: Our partnership with Hydag AG will not influence the financial performance of 2023. The accumulated value over the 3-year contractual period may reach up to 3 million DKK.

A Strong Commitment to Sustainability:

Both Photocat and Hydag AG share a deep commitment to sustainable practices and technologies. This partnership allows the synergy of expertise and innovation to drive change in various industries and for various types of stakeholders – promoting cleaner air, more energy-efficient de-icing processes, and self-sustaining environments.

Flavio Gregori (Chairman and CEO of Hydag AG) and Jesper Elsgaard (CBO of Photocat A/S) are enthusiastic about the possibilities this partnership holds and are fully committed to leveraging their respective strengths to create a brighter and more sustainable future in Switzerland.

A Glimpse into the Future:

This partnership is set to accelerate the adoption of innovative solutions that enhance sustainability and reduce the environmental footprint. By combining Photocat's CMA suite of products and photocatalytic technologies with Hydag AG's expertise, we are confident in the positive impact we can make on the environmental health for Swiss inhabitants.

For further information, please contact:
Jesper Elsgaard
Chief Business Officer
Photocat A/S
Tel: +45 5121 7651

About Photocat A/S:
Photocat is a leading innovator in sustainable solutions, dedicated to harnessing the power of photocatalysis to create a cleaner and more sustainable world as well as eco-friendly and efficient de-icing and dust-suppression solutions. With a focus on cutting-edge technologies and partnerships, Photocat is at the forefront of environmental innovation. Photocat’s shares are listed on Nasdaq Stockholm, First North with the ticker symbol PCAT. The company’s Certified Advisor is Mangold Fondkommission AB.

About Hydag AG:
Hydag AG is a Swiss leader for techno-chemical products used for the prevention of scale and corrosion in steam generators and district heating systems. Their commitment to deliver innovative products and technologies aligns seamlessly with Photocat's mission to advance sustainability and reduce environmental impact.

Photocat A/S (publ) l Langebjerg 4 DK-4000 Roskilde l Tel: +45 7022 5055 l


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release

Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of​ the delisting ​procedure and ​consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab23.2.2024 23:35:31 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will, with the exception of deferred annual cash bonus, be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,013. The restricted stock units will vest on the first ban

HiddenA line styled icon from Orion Icon Library.Eye